GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Microba Life Sciences Ltd (ASX:MAP) » Definitions » Total Liabilities

Microba Life Sciences (ASX:MAP) Total Liabilities : A$16.82 Mil (As of Jun. 2024)


View and export this data going back to 2022. Start your Free Trial

What is Microba Life Sciences Total Liabilities?

Microba Life Sciences's Total Liabilities for the quarter that ended in Jun. 2024 was A$16.82 Mil.

Microba Life Sciences's quarterly Total Liabilities increased from Jun. 2023 (A$8.38 Mil) to Dec. 2023 (A$15.99 Mil) and increased from Dec. 2023 (A$15.99 Mil) to Jun. 2024 (A$16.82 Mil).

Microba Life Sciences's annual Total Liabilities increased from Jun. 2022 (A$5.94 Mil) to Jun. 2023 (A$8.38 Mil) and increased from Jun. 2023 (A$8.38 Mil) to Jun. 2024 (A$16.82 Mil).

Microba Life Sciences Total Liabilities Historical Data

The historical data trend for Microba Life Sciences's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Microba Life Sciences Total Liabilities Chart

Microba Life Sciences Annual Data
Trend Jun22 Jun23 Jun24
Total Liabilities
5.94 8.38 16.82

Microba Life Sciences Semi-Annual Data
Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
Total Liabilities Get a 7-Day Free Trial 5.94 6.28 8.38 15.99 16.82

Microba Life Sciences Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Microba Life Sciences's Total Liabilities for the fiscal year that ended in Jun. 2024 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=12.367+(0.373+2.293
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit)
+1.565+0.226)
=16.82

Total Liabilities=Total Assets (A: Jun. 2024 )-Total Equity (A: Jun. 2024 )
=58.04-41.216
=16.82

Microba Life Sciences's Total Liabilities for the quarter that ended in Jun. 2024 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=12.367+(0.373+2.293
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit)
+1.565+0.226)
=16.82

Total Liabilities=Total Assets (Q: Jun. 2024 )-Total Equity (Q: Jun. 2024 )
=58.04-41.216
=16.82

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Microba Life Sciences Total Liabilities Related Terms

Thank you for viewing the detailed overview of Microba Life Sciences's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Microba Life Sciences Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Microba Life Sciences Ltd (ASX:MAP) » Definitions » Total Liabilities
Comparable Companies
ASX:GSS ASX:IIQ ASX:RHY ASX:LDX ASX:CTE ASX:GTG ASX:BDX ASX:IBX TMO DHR SHSE:603259 IQV IDXX A XSWX:LONN MTD ICLR LH ILMN DGX
Traded in Other Exchanges
N/A
Address
324 Queen Street, Level 10, Brisbane, QLD, AUS, 4000
Website
https://www.microba.com
Microba Life Sciences Ltd is a commercial-stage company with technology for measuring the human gut microbiome and engages in providing gut microbiome testing services globally to consumers, clinicians, and researchers. It is also involved in developing new pathology services, therapeutics, and diagnostics based on the human gut microbiome. The company's operating segments are; Testing Services and Supplements which derives key revenue, and Research and Development. Geographically, the company derives maximum revenue from Australia and the rest from Europe, New Zealand, the United States, Asia, and other regions.

Microba Life Sciences Headlines

No Headlines